Co-Diagnostics (FRA:C97) Total Current Assets : €30.84 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Co-Diagnostics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Co-Diagnostics's total current assets for the quarter that ended in Dec. 2024 was €30.84 Mil.

Co-Diagnostics Total Current Assets Historical Data

The historical data trend for Co-Diagnostics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Total Current Assets Chart

Co-Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

55.74

101.88

87.54

56.98

30.84

Co-Diagnostics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															56.98	49.40	44.80	36.13	30.84

Co-Diagnostics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Co-Diagnostics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	28.409	+	0.127	+	1.025	+	1.278
	=	30.84

Co-Diagnostics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	28.409	+	0.127	+	1.025	+	1.278
	=	30.84

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Co-Diagnostics (FRA:C97) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Co-Diagnostics's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	28.409	-	9.252	+	0.75 * 0.127	+	0.5 * 1.025
=	19.76

Co-Diagnostics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (FRA:C97) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

CODX:USA 0A50:UK C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Co-Diagnostics Headlines

No Headlines